- Home
- PBYI vs PIM Comparison
PBYI vs PIM Comparison
Compare PBYI & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBYI | PIM |
|---|---|---|
| Founded | 2010 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 161.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PBYI | PIM |
|---|---|---|
| Price | $6.41 | $3.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 366.8K | 57.5K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.28% |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | 0.05 |
| Revenue | ★ $211,995,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $8.63 | $63.80 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.58 | $2.90 |
| 52 Week High | $6.44 | $3.28 |
Technical Indicators
Market Signals| Indicator | PBYI | PIM |
|---|---|---|
| Relative Strength Index (RSI) | 67.63 | 53.14 |
| Support Level | $6.05 | $3.29 |
| Resistance Level | $6.29 | $3.36 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 95.76 | 42.31 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.